Study of the Immune Response in Colon Adenocarcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-02-05

Study Completion Date

2024-02-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Duration of each part of the study per patient:

* Screening: From 1 to 4 weeks
* Sampling period (blood and tissue): 1 day
* Follow-up by patient: 60 months
* Total study duration by patient: 84 months
* Total inclusion duration: 24 months
* Total Follow-up duration: 60 months
* Total study duration: 84 months

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study and Modulation of Immune Responses in Primary and Metastatic Colon Cancers

NCT06435689

Colon Cancer Peritoneal Carcinoma

NOT_YET_RECRUITING

Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers

NCT03799731

Colorectal Cancer

COMPLETED PHASE2

Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers

NCT04491955

Small Bowel Cancers Colorectal Cancers

COMPLETED PHASE2

Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

NCT01605318

Metastatic Colorectal Cancer Colon Cancer Rectal Cancer

TERMINATED PHASE1/PHASE2

Test of CD47-SIRPα Inhibitors on the Immune Microenvironment Colon Cancer

NCT05955196

Cancer of the Colon

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colon Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients aged 18 or more.
2. Affiliation to a social security scheme
3. Diagnosis of a colon adenocarcinoma.
4. Patient have signed and dated consent of the study before undertaking procedures related to the study.

Exclusion Criteria

1. Patients under guardianship / curatorship
2. Following Situations

* Persons unable to understand, read and / or sign an informed consent
* Patient with the following functions: investigator or co-investigator, research assistant, pharmacist, study coordinator or having any involvement in the study
* Uncooperative person or potentially non-compliant for the study and its procedures with predictable difficulties regular monitoring of over 1 year.
* No affiliation to a social security scheme, a universal medical coverage or any similar plan.
3. Pregnant or lactating women.
4. Patients with HIV seropositivity.
5. Rectal tumor location.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No